Sharma A, et al. - Given the risk for bleeding and subsequent adverse non–bleeding-related events among patients with a recent acute coronary syndrome (ACS) receiving oral antiplatelets and anticoagulants, researchers assessed clinical events during a 30-day period after Thrombolysis in Myocardial Infarction (TIMI) major/minor bleeding. This post hoc analysis included 7,392 high-risk patients (median follow-up 241 days) with a recent ACS who were randomized to apixaban or placebo. During follow-up, TIMI major/minor bleeding was reported in 153 (2.1%) patients. They noted significantly increased risk of ensuing ischemic events and mortality in correlation to bleeding. This risk was noted irrespective of antithrombotic or anticoagulant strategy. Bleeding risk was comparable for patients receiving apixaban plus aspirin vs those receiving thienopyridine plus aspirin.